125 related articles for article (PubMed ID: 30160395)
1. Economic implications with newer agents to reduce cardiovascular risk in diabetes.
McAdam-Marx C
Am J Manag Care; 2018 Aug; 24(13 Suppl):S279-S285. PubMed ID: 30160395
[TBL] [Abstract][Full Text] [Related]
2. The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.
Hoerger TJ; Ahmann AJ
J Manag Care Pharm; 2008 Feb; 14(1 Suppl C):S2-14; quiz 15-6. PubMed ID: 18240890
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Rahelic D; Ceriello A
Cardiovasc Diabetol; 2017 Mar; 16(1):35. PubMed ID: 28284218
[TBL] [Abstract][Full Text] [Related]
5. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
Lovre D; Htun W; Carrion C; Fonseca VA
Curr Diab Rep; 2016 Oct; 16(10):94. PubMed ID: 27541296
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Expenditure and Productivity Cost Savings from Reductions in Cardiovascular Disease and Type 2 Diabetes Associated with Increased Intake of Cereal Fibre among Australian Adults: A Cost of Illness Analysis.
Fayet-Moore F; George A; Cassettari T; Yulin L; Tuck K; Pezzullo L
Nutrients; 2018 Jan; 10(1):. PubMed ID: 29301298
[TBL] [Abstract][Full Text] [Related]
7. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment.
Veenstra DL; Ramsey SD; Sullivan SD
Pharmacoeconomics; 2002; 20 Suppl 1():21-30. PubMed ID: 12036381
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on cardiovascular outcome trials in diabetes.
Schnell O; Rydén L; Standl E; Ceriello A;
Cardiovasc Diabetol; 2016 Oct; 15(1):139. PubMed ID: 27716274
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes.
Chilton RJ; Dungan KM; Shubrook JH; Umpierrez GE
Prim Care Diabetes; 2020 Jun; 14(3):193-212. PubMed ID: 31704161
[TBL] [Abstract][Full Text] [Related]
10. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
11. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
Giugliano D; Maiorino MI; Bellastella G; Esposito K
Endocrine; 2018 May; 60(2):224-228. PubMed ID: 28895030
[TBL] [Abstract][Full Text] [Related]
12. Economics of diabetes-cost impact of not treating diabetes early and intensively.
Cefalu W
Clin Cornerstone; 2004; 6(2):51-60. PubMed ID: 15628693
[TBL] [Abstract][Full Text] [Related]
13. Elevated Costs and Healthcare Resource Utilization in Patients With Type 2 Diabetes and Established Cardiovascular Disease in Israel.
Melzer Cohen C; Hallén N; Chodick G; Bourvine L; Waner T; Karasik A
Value Health Reg Issues; 2020 Sep; 22():83-92. PubMed ID: 32798839
[TBL] [Abstract][Full Text] [Related]
14. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
Palmer AJ; Tucker DM
Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
[TBL] [Abstract][Full Text] [Related]
15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
16. Estimation and Prediction of Avoidable Health Care Costs of Cardiovascular Diseases and Type 2 Diabetes Through Adequate Dairy Food Consumption: A Systematic Review and Micro Simulation Modeling Study.
Javanbakht M; Jamshidi AR; Baradaran HR; Mohammadi Z; Mashayekhi A; Shokraneh F; Rezai Hamami M; Yazdani Bakhsh R; Shabaninejad H; Delavari S; Tehrani A
Arch Iran Med; 2018 May; 21(5):213-222. PubMed ID: 29738265
[TBL] [Abstract][Full Text] [Related]
17. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
18. Canadian Potential Healthcare and Societal Cost Savings from Consumption of Pulses: A Cost-Of-Illness Analysis.
Abdullah MMH; Marinangeli CPF; Jones PJH; Carlberg JG
Nutrients; 2017 Jul; 9(7):. PubMed ID: 28737688
[TBL] [Abstract][Full Text] [Related]
19. Impact of Treating Oral Disease on Preventing Vascular Diseases: A Model-Based Cost-effectiveness Analysis of Periodontal Treatment Among Patients With Type 2 Diabetes.
Choi SE; Sima C; Pandya A
Diabetes Care; 2020 Mar; 43(3):563-571. PubMed ID: 31882408
[TBL] [Abstract][Full Text] [Related]
20. The burden of cardiovascular disease in patients with diabetes.
Hudspeth B
Am J Manag Care; 2018 Aug; 24(13 Suppl):S268-S272. PubMed ID: 30160393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
